Physician profile
Daniel Peterson
NPI 1194411355
$3,863.24
in general payments reported to CMS, 2019-2025
24 companies · $2,470 in 2025
The $2,470 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $42.17 · 2024: $1,351 · 2025: $2,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,041 · Travel and Lodging: $814 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,041.24 |
| Travel and Lodging | $814.04 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,212.39 | 2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $338.14 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $307.32 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $229.27 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Beta Bionics, INC. | $195.08 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascensia Diabetes Care US INC. | $189.95 | 2024-2025 | |
| Amgen INC. | $177.22 | 2025 | Evenity, Tepezza |
| Sanofi-Aventis U.S. LLC | $162.99 | 2024-2025 | |
| Abbvie INC. | $156.87 | 2025 | |
| Tandem Diabetes Care, INC. | $131.28 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $120.34 | 2024-2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $107.26 | 2024 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $66.57 | 2024-2025 | |
| Radius Health, INC. | $63.55 | 2024-2025 | Tymlos |
| Neurocrine Biosciences, INC. | $60.28 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $58.92 | 2025 | Yorvipath |
| Boston Scientific Corporation | $58.89 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Corcept Therapeutics | $57.54 | 2024 | Korlym |
| Madrigal Pharmaceuticals | $48.29 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $47.54 | 2024-2025 | Isturisa, Signifor Lar |
| Novartis Pharmaceuticals Corporation | $21.91 | 2024 | |
| Acella Pharmaceuticals, LLC | $20.80 | 2024 | NP Thyroid 60 |
| Antares Pharma, INC. | $16.57 | 2024 | Xyosted |
| Astellas Pharma US INC | $14.27 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.